Boryung exclusively to distribute a new peptic ulcer drug.

Published: 2005-06-09 06:56:00

Updated: 2005-06-09 06:56:00

Boryung made a technical licence agreement with UCB S.A, a Japanese subsidiary of UCB at Boryung building on June 3 for the exclusive distribution of Stogar, a new H2 receptor antagonist drug for the treatment of peptic ulcer.

It shows a sustained blocking activity against the gastric acid exc...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK